KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortization of Deferred Charges (2018 - 2022)

Historic Amortization of Deferred Charges for TherapeuticsMD (TXMD) over the last 7 years, with Q3 2022 value amounting to $2.6 million.

  • TherapeuticsMD's Amortization of Deferred Charges rose 7481.38% to $2.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $21.1 million, marking a year-over-year increase of 31791.87%. This contributed to the annual value of $5.7 million for FY2021, which is 12468.4% up from last year.
  • Per TherapeuticsMD's latest filing, its Amortization of Deferred Charges stood at $2.6 million for Q3 2022, which was up 7481.38% from $7.9 million recorded in Q2 2022.
  • In the past 5 years, TherapeuticsMD's Amortization of Deferred Charges registered a high of $9.0 million during Q1 2022, and its lowest value of $119753.0 during Q3 2018.
  • Its 5-year average for Amortization of Deferred Charges is $1.7 million, with a median of $887000.0 in 2020.
  • In the last 5 years, TherapeuticsMD's Amortization of Deferred Charges skyrocketed by 5498.43% in 2021 and then soared by 61132.08% in 2022.
  • Quarter analysis of 5 years shows TherapeuticsMD's Amortization of Deferred Charges stood at $119950.0 in 2018, then skyrocketed by 127.74% to $273171.0 in 2019, then skyrocketed by 224.71% to $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then surged by 68.65% to $2.6 million in 2022.
  • Its Amortization of Deferred Charges was $2.6 million in Q3 2022, compared to $7.9 million in Q2 2022 and $9.0 million in Q1 2022.